close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

36.37 -1.44 (-3.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
News headline image
Nasdaq Down Over 300 Points; Medtronic Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Why Novo Nordisk Stock Popped Today ↗
For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop. 
Via The Motley Fool
This Drugmaker Stock Slumped 36% In Tuesday’s Premarket Session: Here’s Why ↗
Via Stocktwits
News headline image
Why Viking Therapeutics Stock Crashed Today ↗
Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable? 
Via The Motley Fool
News headline image
US Stocks Mixed; Home Depot Shares Gain After Q2 Results ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks ↗
Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo. 
Via Benzinga
News headline image
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill ↗
Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735. 
Via Investor's Business Daily
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stock Market Today: S&P 500 Slips, Dow Futures Rise—Intel, Palo Alto, Home Depot In Focus ↗
U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
News headline image
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond ↗
Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for something BIG." 
Via Benzinga
Topics Bonds
News headline image
Predicting the Next Rule Breaker Buyout ↗
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Viking Therapeutics Stock Zoomed 5% Higher Today ↗
The company is a front-runner in the race to develop an orally administered weight loss drug. 
Via The Motley Fool
News headline image
1 Beaten-Down Stock That Could Soar by the End of the Year ↗
The drugmaker has a major catalyst on the way. 
Via The Motley Fool
News headline image
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. ↗
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
News headline image
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst ↗
William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback. 
Via Benzinga
News headline image
The 3 Things That Matter for Viking Therapeutics Now ↗
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
News headline image
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today ↗
The biopharmaceutical company has an exciting lead compound in development. 
Via The Motley Fool
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗
Via Stocktwits
News headline image
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
News headline image
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
News headline image
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
News headline image
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
News headline image
Is It Time to Buy Biotech Stocks? ↗
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
News headline image
This Biotech Stock Could Soar on Upcoming Clinical Data ↗
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
News headline image
2 Beaten-Down Stocks With Incredible Upside Potential ↗
Getting in on the ground floor with these companies might lead to superior returns. 
Via The Motley Fool
News headline image
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.